The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells

INTRODUCTION: Medroxyprogesterone acetate (MPA), the major progestin used for oral contraception and hormone replacement therapy, has been implicated in increased breast cancer risk. Is this risk due to its progestational or androgenic properties? To address this, we assessed the transcriptional eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghatge, Radhika P, Jacobsen, Britta M, Schittone, Stephanie A, Horwitz, Kathryn B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410743/
https://www.ncbi.nlm.nih.gov/pubmed/16457685
http://dx.doi.org/10.1186/bcr1340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410743/
https://www.ncbi.nlm.nih.gov/pubmed/16457685
http://dx.doi.org/10.1186/bcr1340

Ejemplares similares